Progress in identifying and effectively treating first-episode schizophrenia was marked by the simultaneous publication of a report on a 6-year study and on the 10-year follow-up of a large-scale trial.
A recent meta-analysis supports evidence of the effectiveness of the fixed olanzapine/fluoxetine combination (Symbyax) in treating the depressive phase of bipolar disorder. Response was ranked higher, but with no more adverse effects, than with treatment with olanzapine alone.
Results of a 10-week prospective study, recently reported at the Annual Meeting of the American Association for Geriatric Psychiatry, offered no conclusive evidence about the mortality risk of elderly patients with Alzheimer disease who were treated with antipsychotics.
Given the likelihood that insufficient numbers of patients will be available for a randomized controlled trial of MAOIs in refractory depression or atypical depression, we must still rely on consensus guidelines and expert opinion.